These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24782221)

  • 1. The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
    Karaźniewicz-Łada M; Danielak D; Rubiś B; Burchardt P; Oszkinis G; Główka F
    J Clin Pharmacol; 2014 Aug; 54(8):874-80. PubMed ID: 24782221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.
    Kobayashi M; Kajiwara M; Hasegawa S
    J Atheroscler Thromb; 2015; 22(11):1186-96. PubMed ID: 26063503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
    Wang XQ; Shen CL; Wang BN; Huang XH; Hu ZL; Li J
    Gene; 2015 Mar; 558(2):200-7. PubMed ID: 25542807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.
    Kim HS; Lim Y; Oh M; Ghim JL; Kim EY; Kim DH; Shin JG
    Br J Clin Pharmacol; 2016 Feb; 81(2):301-12. PubMed ID: 26426352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.
    Kim KA; Park PW; Hong SJ; Park JY
    Clin Pharmacol Ther; 2008 Aug; 84(2):236-42. PubMed ID: 18323861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel.
    Danielak D; Karaźniewicz-Łada M; Wiśniewska K; Bergus P; Burchardt P; Komosa A; Główka F
    Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):99-107. PubMed ID: 26891871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration.
    Kim HS; Cho DY; Park BM; Bae SK; Yoon YJ; Oh M; Ghim JL; Kim EY; Kim DH; Shin JG
    J Clin Pharmacol; 2014 Aug; 54(8):850-7. PubMed ID: 24214141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
    Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
    Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting.
    González A; Moniche F; Cayuela A; García-Lozano JR; Torrecillas F; Escudero-Martínez I; Gonzalez-Marcos JR; Mayol A; Montaner J
    Eur J Vasc Endovasc Surg; 2016 Feb; 51(2):175-86. PubMed ID: 26526111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.
    Pedersen RS; Nielsen F; Stage TB; Vinholt PJ; el Achwah AB; Damkier P; Brosen K
    Clin Exp Pharmacol Physiol; 2014 Nov; 41(11):870-8. PubMed ID: 25115434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
    Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
    Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites.
    Karaźniewicz-Łada M; Danielak D; Rubiś B; Burchardt P; Komosa A; Lesiak M; Główka F
    J Clin Pharm Ther; 2015 Apr; 40(2):226-31. PubMed ID: 25430046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
    Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
    J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.
    Hokimoto S; Akasaka T; Tabata N; Arima Y; Tsujita K; Sakamoto K; Kaikita K; Morita K; Kumagae N; Yamamoto E; Oniki K; Nakagawa K; Ogawa H
    Thromb Res; 2015 Jun; 135(6):1081-6. PubMed ID: 25891840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.
    Horenstein RB; Madabushi R; Zineh I; Yerges-Armstrong LM; Peer CJ; Schuck RN; Figg WD; Shuldiner AR; Pacanowski MA
    J Clin Pharmacol; 2014 Aug; 54(8):865-73. PubMed ID: 24710841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
    Karaźniewicz-Łada M; Danielak D; Burchardt P; Kruszyna L; Komosa A; Lesiak M; Główka F
    Clin Pharmacokinet; 2014 Feb; 53(2):155-64. PubMed ID: 24127209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.
    Gong IY; Crown N; Suen CM; Schwarz UI; Dresser GK; Knauer MJ; Sugiyama D; DeGorter MK; Woolsey S; Tirona RG; Kim RB
    Eur Heart J; 2012 Nov; 33(22):2856-2464a. PubMed ID: 22374717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention.
    Adamiak-Giera U; Czerkawska A; Olędzki S; Kurzawski M; Safranow K; Jastrzębska M; Gawrońska-Szklarz B
    Pharmacol Rep; 2021 Apr; 73(2):583-593. PubMed ID: 33270185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects.
    Song BL; Wan M; Tang D; Sun C; Zhu YB; Linda N; Fan HW; Zou JJ
    Clin Ther; 2018 Jul; 40(7):1170-1178. PubMed ID: 30017169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.
    Simon T; Bhatt DL; Bergougnan L; Farenc C; Pearson K; Perrin L; Vicaut E; Lacreta F; Hurbin F; Dubar M
    Clin Pharmacol Ther; 2011 Aug; 90(2):287-95. PubMed ID: 21716274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.